Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of REVITALIZE: A Telehealth Intervention to Reduce Fatigue Interference Among Adults With Advanced Ovarian Cancer on PARP Inhibitors

NCT06710548 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06710548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06710548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of REVITALIZE: A Telehealth Intervention to Reduce Fatigue Interference Among Adults With Advanced Ovarian Cancer on PARP Inhibitors
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
March 17, 2025
Completion date
January 31, 2029
Enrollment
240 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ovarian carcinoma, fallopian tube carcinoma, fatigue in cancer survivors, fatigue related to cancer treatment, ovarian cancer, parp inhibitor, primary peritoneal cancer